US1538678A
(en)
*
|
1923-02-24 |
1925-05-19 |
Joseph S Blinn |
Suppository injector
|
US3791385A
(en)
*
|
1972-10-16 |
1974-02-12 |
A Davis |
Catamenial device and applicator thereof
|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
EP0478797B1
(de)
|
1990-04-20 |
1995-04-12 |
Hisayuki Matsuo |
Neue im schwein vorkommende physiologisch aktive peptide
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド(cnp―53)
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタcnp遺伝子及び前駆体蛋白
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド(カエルcnp)
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド(ニワトリcnp)
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットCNPcDNA及び前駆体蛋白
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトcnp遺伝子及び前駆体蛋白
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Cnp類似体ペプチド
|
WO1992020371A1
(en)
*
|
1991-05-10 |
1992-11-26 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
AU6360394A
(en)
|
1993-03-03 |
1994-09-26 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
WO1995005455A1
(en)
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
DK0728147T3
(da)
|
1993-11-12 |
2003-06-10 |
Genentech Inc |
Receptorspecifikke atrienatriuretiske peptider
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
JPH10500969A
(ja)
|
1994-06-02 |
1998-01-27 |
ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング |
カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
US5863782A
(en)
*
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
JP2001503256A
(ja)
|
1996-10-22 |
2001-03-13 |
ジェネンテック,インコーポレーテッド |
レセプター選択的bnp
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
WO2000053755A2
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor
|
US6455495B1
(en)
|
1997-02-14 |
2002-09-24 |
The Salk Institute For Biological Studies |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
WO1999046283A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
CA2245903A1
(en)
*
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
CA2262056A1
(en)
*
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
JP2002542304A
(ja)
|
1999-04-28 |
2002-12-10 |
ベクトレイムド インコーポレイテッド |
酵素的に活性化された重合薬物接合体
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
JP2000327583A
(ja)
*
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
CA2499211A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem Inc. |
Modified peptides yy and conjugates thereof
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
AU1920201A
(en)
|
1999-11-16 |
2001-05-30 |
Genzyme Corporation |
Improved regulatory elements for delivery to the liver
|
AU2583901A
(en)
|
1999-12-17 |
2001-06-25 |
Ariad Pharmaceuticals, Inc. |
Proton pump inhibitors
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
EP1502604A1
(de)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Verwendung von Stickstoffoxid-Mimetika in der Behandlung von Krebs
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
EP1278547B1
(de)
|
2000-04-26 |
2004-11-03 |
Cellegy Pharmaceuticals, Inc |
Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
AU2001287429B2
(en)
*
|
2000-08-23 |
2005-08-18 |
Alexion Pharmaceuticals, Inc. |
Method and compositions for promoting osteogenesis
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
EA005584B1
(ru)
|
2000-12-07 |
2005-04-28 |
Эли Лилли Энд Компани |
Слитые белки glp-1
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
WO2002068579A2
(en)
|
2001-01-10 |
2002-09-06 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
WO2002092020A2
(en)
*
|
2001-03-23 |
2002-11-21 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
US7888372B2
(en)
*
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
US6808905B2
(en)
*
|
2001-05-14 |
2004-10-26 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
CA2652991A1
(en)
|
2001-07-16 |
2003-11-13 |
Caprotec Bioanalytics Gmbh |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
US6610025B2
(en)
*
|
2001-08-06 |
2003-08-26 |
The Procter & Gamble Company |
Tampon applicator arrangement
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
AU2002356392A1
(en)
|
2001-12-20 |
2003-07-09 |
Phenogene Therapeutiques Inc. |
Bone polypeptide-1
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030158132A1
(en)
*
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
CA2478145A1
(en)
|
2002-03-06 |
2003-09-12 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
WO2003079979A2
(en)
|
2002-03-18 |
2003-10-02 |
Scios Inc. |
Method for treating congestive heart failure
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
CA2433479A1
(en)
*
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
JP2006514607A
(ja)
|
2002-07-31 |
2006-05-11 |
コンジュケム,インコーポレーテッド |
長時間持続性ナトリウム排泄増加性ペプチド誘導体
|
WO2004022579A2
(en)
|
2002-09-06 |
2004-03-18 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
CA2511680A1
(en)
|
2002-11-18 |
2004-06-03 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
DE60331584D1
(de)
|
2002-11-26 |
2010-04-15 |
Biocon Ltd |
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
|
AU2003291867A1
(en)
|
2002-12-03 |
2004-06-23 |
Biomep Inc. |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
EP1583554A2
(de)
|
2003-01-13 |
2005-10-12 |
Gudrun Rappold-Hoerbrand |
Verwendung eines natriuretischen peptids zur behandlung von mit shox gen verbundenen wachstumsstörungen
|
US20060228710A1
(en)
|
2003-02-14 |
2006-10-12 |
Morris David W |
Novel therapeutic targets in cancer
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
WO2004094460A2
(en)
|
2003-04-17 |
2004-11-04 |
Ciphergen Biosystems, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
EP1635872A4
(de)
*
|
2003-05-30 |
2008-01-02 |
Alexion Pharma Inc |
Antikörper und fusionsproteine mit manipulierten konstanten regionen
|
EP1644740B1
(de)
|
2003-06-17 |
2010-12-01 |
Otago Innovation Limited |
Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
|
ES2354881T3
(es)
|
2003-06-20 |
2011-03-18 |
Mayo Foundation For Medical Education And Research |
Isoformas de péptido natriurético cerebral.
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
KR100725315B1
(ko)
|
2003-11-13 |
2007-06-07 |
한미약품 주식회사 |
면역글로불린 단편을 이용한 단백질 결합체 및 그의제조방법
|
US20060019890A1
(en)
|
2004-01-15 |
2006-01-26 |
Kapoun Ann M |
Method for treating cardiac remodeling following myocardial injury
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
EP1730181A2
(de)
|
2004-01-27 |
2006-12-13 |
Compugen USA, Inc. |
Neue natriuretische peptidvarianten im gehirn und anwendungsverfahren
|
KR101207155B1
(ko)
|
2004-03-31 |
2012-12-04 |
카즈와 나카오 |
관절염증 치료제 또는 예방제
|
US8815803B2
(en)
|
2004-03-31 |
2014-08-26 |
Kazuwa Nakao |
Method for increasing body height comprising systemic administration of CNP-53
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
EP3404102B1
(de)
*
|
2004-04-21 |
2021-08-11 |
Alexion Pharmaceuticals, Inc. |
Knochenfreisetzungskonjugate und verfahren zur verwendung davon zum zielen von proteinen auf knochen
|
CA2566346A1
(en)
|
2004-05-10 |
2005-11-24 |
Novacea, Inc. |
Prevention of arterial restenosis with active vitamin d compounds
|
US7863238B2
(en)
*
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
US7972593B2
(en)
*
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
US20070081984A1
(en)
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
DE602005026014D1
(de)
|
2004-07-15 |
2011-03-03 |
Univ Queensland |
Proteinartige verbindungen und anwendungen davon
|
US20090142347A1
(en)
*
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
WO2006060641A2
(en)
|
2004-12-01 |
2006-06-08 |
Genzyme Corporation |
Methods for targeted delivery of genetic material to the liver
|
DK1865976T3
(da)
|
2005-04-07 |
2012-07-23 |
Cardiopep Pharma Gmbh |
Anvendelse af natriuretiske peptider til behandling af hjertesvigt
|
EP1874816A4
(de)
|
2005-04-26 |
2010-08-25 |
Medimmune Inc |
Modulation der antikörpereffektorfunktion mittels manipulation von verbindungsregionen
|
US20070042957A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
AU2006343306A1
(en)
|
2005-09-06 |
2007-11-15 |
Zelos Therapeutics, Inc. |
Parathyroid hormone analogues and methods of use
|
WO2007035600A2
(en)
|
2005-09-16 |
2007-03-29 |
Mayo Foundation For Education And Research |
Natriuretic activities
|
US20080227713A1
(en)
|
2005-10-03 |
2008-09-18 |
Protter Andrew A |
Oxidized Human Bnp
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
US8575070B2
(en)
|
2006-02-20 |
2013-11-05 |
Phylogica Limited |
Methods of constructing and screening libraries of peptide structures
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
AU2007315790A1
(en)
|
2006-06-30 |
2008-05-08 |
Interface Biologics, Inc. |
Bioresponsive polymers
|
CA2660294C
(en)
|
2006-08-08 |
2017-08-29 |
Mayo Foundation For Medical Education And Research |
Diuretic and natriuretic polypeptides
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
WO2008031045A2
(en)
|
2006-09-08 |
2008-03-13 |
Mayo Foundation For Medical Education And Research |
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
|
EP2069396B1
(de)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modifiziertes polypeptid oder fc-gerüste aus humanem plasma und ihre verwendung
|
TW200833840A
(en)
*
|
2006-10-25 |
2008-08-16 |
Amgen Inc |
Toxin peptide therapeutic agents
|
US20100168443A1
(en)
|
2006-11-02 |
2010-07-01 |
University Of Virginia Patent Foundation |
Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
|
CN101668421B
(zh)
|
2006-11-16 |
2014-05-21 |
凯制药公司 |
用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
|
US20080181903A1
(en)
*
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
RU2462719C2
(ru)
|
2007-03-12 |
2012-09-27 |
Биомедика Медицинпродукте Гмбх Унд Ко Кг |
Диагностика септических осложнений
|
EP1985697A1
(de)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modifizierte Phosphatasen
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
HUE031655T2
(hu)
|
2007-05-11 |
2017-07-28 |
Alexion Pharma Inc |
Csontot targetáló alkálikus foszfatáz, készletek és eljárások alkalmazásukra
|
KR20100021601A
(ko)
|
2007-05-14 |
2010-02-25 |
바이오겐 아이덱 엠에이 인코포레이티드 |
단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
|
US20100310561A1
(en)
|
2007-06-06 |
2010-12-09 |
Boehringer Ingelheim International Gmbh |
Natriuretic fusion proteins
|
EP2171451A4
(de)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Verfahren zur behandlung juveniler idiopathischer arthritis
|
WO2009006520A1
(en)
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
JP2010532323A
(ja)
|
2007-07-06 |
2010-10-07 |
セラテクノロジーズ インコーポレイテッド |
アルファ−メラニン細胞刺激ホルモン(アルファ−msh)および心房性ナトリウム利尿タンパク質(anp)の二機能性融合タンパク質ならびに高血圧および急性腎臓損傷における使用
|
AU2008279379B2
(en)
|
2007-07-20 |
2016-03-24 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
US20090053192A1
(en)
|
2007-08-10 |
2009-02-26 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
EP2185701A4
(de)
|
2007-08-15 |
2011-03-02 |
Amunix Operating Inc |
Zusammensetzungen und verfahren zur veränderung von eigenschaften biologisch aktiver polypeptide
|
AU2008297893A1
(en)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a deslorelin and mastoparan as a therapeutic agent
|
WO2009043527A2
(en)
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Therapeutic use of human growth hormone 1-43
|
ES2575397T3
(es)
|
2007-09-11 |
2016-06-28 |
Cardiopep Pharma Gmbh |
Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
|
JP2010539065A
(ja)
*
|
2007-09-11 |
2010-12-16 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
治療剤としてのペプチドの使用
|
AU2008303900A1
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of a galanin peptide as a therapeutic agent
|
AU2008303945A1
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
WO2009036448A2
(en)
|
2007-09-15 |
2009-03-19 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-c agonists
|
AR069409A1
(es)
|
2007-11-21 |
2010-01-20 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2080812A1
(de)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Zusammensetzungen und Verfahren zur Detektion von Post-Stopp-Peptiden
|
EP2277890B1
(de)
|
2008-05-23 |
2016-01-06 |
Daiichi Sankyo Company, Limited |
Zur verlängerung der halbwertzeit eines peptids von interesse in einem plasma geeignetes peptid
|
US20110152194A1
(en)
|
2008-06-06 |
2011-06-23 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
EP2315602A4
(de)
|
2008-06-26 |
2011-11-02 |
Acceleron Pharma Inc |
Verfahren zur dosierung eines actriib-antagonisten und überwachung von behandelten patienten
|
US8741842B2
(en)
|
2008-07-02 |
2014-06-03 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides with unique pharmacologic profiles
|
NZ590358A
(en)
|
2008-07-23 |
2012-04-27 |
Hanmi Holdings Co Ltd |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
WO2010048308A2
(en)
|
2008-10-24 |
2010-04-29 |
Deborah Dickey |
Natriuretic polypeptides
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
KR20100084996A
(ko)
|
2009-01-19 |
2010-07-28 |
한미홀딩스 주식회사 |
면역글로불린 단편을 이용한 생리활성 단백질 또는 펩타이드의 생산 방법
|
CA2754408A1
(en)
|
2009-03-30 |
2010-10-14 |
Boehringer Ingelheim International Gmbh |
Fusion proteins comprising canine fc portions
|
WO2010129655A2
(en)
|
2009-05-05 |
2010-11-11 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
RU2573911C2
(ru)
|
2009-05-20 |
2016-01-27 |
Байомарин Фармасьютикал Инк. |
Варианты натрийуретического пептида с-типа
|
CN103153344A
(zh)
|
2010-04-30 |
2013-06-12 |
阿莱克森国际制药有限公司 |
用于治疗基质矿化障碍的方法、组合物、和试剂盒
|
AU2011350066A1
(en)
|
2010-12-27 |
2013-07-11 |
Alexion Pharma International Sarl |
Compositions comprising natriuretic peptides and methods of use thereof
|
SG11201401605QA
(en)
|
2011-10-19 |
2014-09-26 |
Alexion Pharma Holding |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
WO2013071262A1
(en)
|
2011-11-10 |
2013-05-16 |
Kai Pharmaceuticals, Inc. |
Calcimimetics and methods for their use
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
EP2877247A1
(de)
|
2012-07-25 |
2015-06-03 |
Psioxus Therapeutics Limited |
Verwendung von s-pindolol zur behandlung von kachexie und sarkopenie
|
PL3461891T3
(pl)
|
2014-01-24 |
2020-11-16 |
Am-Pharma B.V. |
Przetwarzanie końcowe fosfatazy alkalicznej
|
AU2015275128C1
(en)
|
2014-06-09 |
2020-02-13 |
Kyowa Kirin Co., Ltd. |
The effective and efficient control of serum phosphate for optimal bone formation
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
BR112017011900A2
(pt)
|
2014-12-05 |
2018-02-27 |
Alexion Pharma Inc |
tratamento de ataques com fosfatase alcalina recombinante
|
JP6868561B2
(ja)
|
2015-01-28 |
2021-05-12 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
アルカリホスファターゼ欠損を有する被験者を治療する方法
|
MX2018002121A
(es)
|
2015-08-17 |
2018-06-18 |
Alexion Pharma Inc |
Elaboracion de fosfatasas alcalinas.
|
US11229686B2
(en)
|
2015-09-28 |
2022-01-25 |
Alexion Pharmaceuticals, Inc. |
Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
|
WO2017074466A1
(en)
|
2015-10-30 |
2017-05-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
WO2017155569A1
(en)
|
2016-03-08 |
2017-09-14 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
WO2017173413A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Treating muscle weakness with alkaline phosphatases
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
EP3474886B1
(de)
|
2016-06-27 |
2021-08-04 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung von hypophosphatasie bei kindern und jugendlichen
|
EP3500289A4
(de)
|
2016-08-18 |
2020-05-06 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung von tracheobronchomalazie
|